Sclerostin downregulation in aseptic loosening
- 1Department of Trauma and Orthopaedic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- 2Helios ENDO-Klinik Hamburg, Hamburg, Germany.
Abstract
Aims
Aseptic loosening is one of the leading indications for revision surgery after total hip and knee arthroplasty, yet its diagnosis and underlying mechanisms remain poorly defined. In this exploratory study, we investigated synovial fluid biomarkers and periprosthetic bone tissue characteristics to identify molecular signatures associated with aseptic loosening.Methods
A total of 40 patients were included across three groups: primary osteoarthritis (OA; n = 13), aseptic loosening (n = 15), and other aseptic revisions (n = 12). Routine blood tests and synovial cytology were obtained. Synovial fluid underwent targeted proteomic profiling. Trabecular bone was assessed by histomorphometry, quantitative backscattered electron imaging, and immunofluorescence.Results
Routine blood (CRP, white blood cell (WBC) count) and synovial (WBC count and differential) analyses showed no differences between groups, underscoring their limited diagnostic utility. In contrast, bone-focused multiplex synovial fluid profiling identified sclerostin as the strongest discriminatory marker, with significantly lower levels in aseptic loosening than in OA and other aseptic revisions. Dickkopf-1 showed a concordant but weaker reduction, reaching significance versus OA. Histomorphometric analysis of periprosthetic trabecular bone samples demonstrated preserved microarchitecture and turnover across groups. However, quantitative backscattered electron imaging revealed enlarged osteocyte lacunae specifically in aseptic loosening. Immunofluorescence confirmed reduced sclerostin expression within periprosthetic bone, mirroring synovial fluid findings. Synovial sclerostin demonstrated promising diagnostic potential, achieving an area under the curve (AUC) of 0.82 for differentiating aseptic loosening from other revision indications.Conclusion
This study showcases osteocyte dysregulation as a key feature of aseptic loosening, and suggests that reduced osteocyte-derived sclerostin may reflect adaptive responses to abnormal mechanical and inflammatory stimuli at the implant-bone interface. Larger prospective studies are required to validate these findings, but osteocyte-derived sclerostin may represent a promising biomarker and potential therapeutic target in aseptic loosening.
Related
- Early intermittent low-dose sclerostin antibody treatment promotes surface bone formation and reduces bone loss, but also decreases osteocyte apoptosis and mechanotransduction in ovariectomized rats: A pilot study
- Osteoporosis and Alzheimer's Disease: The Role of Sclerostin.
- Radiographic S1 Pedicle Screw Loosening After Lumbosacral Fusion for Degenerative Disease: A Single-Institution Cohort Study
- The Stryker Perform and Univers Apex short stems have different patterns of stress shielding but comparably low rates of loosening after reverse total shoulder arthroplasty
- Bupropion-Induced Aseptic Meningitis: Postmarketing Safety Evaluation and Case Report
BibTeX
@article{alimy2026sclerostin,
title = {{Sclerostin downregulation in aseptic loosening}},
author = {Assil-Ramin Alimy and Eva Goedecke and Ana Ocokoljic and Christian Ries and Frank Timo Beil and Tim Rolvien},
journal = {Bone \& joint research},
year = {2026},
month = nov,
doi = {10.1302/2046-3758.1511.bjr-2025-0796.r1},
url = {https://europepmc.org/article/PMC/PMC13727321},
note = {CC BY},
}
RIS
TY - JOUR
TI - Sclerostin downregulation in aseptic loosening
AU - Assil-Ramin Alimy
AU - Eva Goedecke
AU - Ana Ocokoljic
AU - Christian Ries
AU - Frank Timo Beil
AU - Tim Rolvien
PY - 2026
DA - 2026/11/01
JO - Bone & joint research
DO - 10.1302/2046-3758.1511.bjr-2025-0796.r1
UR - https://europepmc.org/article/PMC/PMC13727321
AB - Aims Aseptic loosening is one of the leading indications for revision surgery after total hip and knee arthroplasty, yet its diagnosis and underlying mechanisms remain poorly defined. In this exploratory study, we investigated synovial fluid biomarkers and periprosthetic bone tissue characteristics to identify molecular signatures associated with aseptic loosening.Methods A total of 40 patients were included across three groups: primary osteoarthritis (OA; n = 13), aseptic loosening (n = 15), and other aseptic revisions (n = 12). Routine blood tests and synovial cytology were obtained. Synovial fluid underwent targeted proteomic profiling. Trabecular bone was assessed by histomorphometry, quantitative backscattered electron imaging, and immunofluorescence.Results Routine blood (CRP, white blood cell (WBC) count) and synovial (WBC count and differential) analyses showed no differences between groups, underscoring their limited diagnostic utility. In contrast, bone-focused multiplex synovial fluid profiling identified sclerostin as the strongest discriminatory marker, with significantly lower levels in aseptic loosening than in OA and other aseptic revisions. Dickkopf-1 showed a concordant but weaker reduction, reaching significance versus OA. Histomorphometric analysis of periprosthetic trabecular bone samples demonstrated preserved microarchitecture and turnover across groups. However, quantitative backscattered electron imaging revealed enlarged osteocyte lacunae specifically in aseptic loosening. Immunofluorescence confirmed reduced sclerostin expression within periprosthetic bone, mirroring synovial fluid findings. Synovial sclerostin demonstrated promising diagnostic potential, achieving an area under the curve (AUC) of 0.82 for differentiating aseptic loosening from other revision indications.Conclusion This study showcases osteocyte dysregulation as a key feature of aseptic loosening, and suggests that reduced osteocyte-derived sclerostin may reflect adaptive responses to abnormal mechanical and inflammatory stimuli at the implant-bone interface. Larger prospective studies are required to validate these findings, but osteocyte-derived sclerostin may represent a promising biomarker and potential therapeutic target in aseptic loosening.
SN - 2046-3758
ER -